Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan

Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A, has been available for the treatment of moderate to severe psoriasis and psoriatic arthritis since February 2015 in Japan. Because there was a time gap after the previous approval of biologics for psoriatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Hideki, Ohtsuki, Mamitaro, Morita, Akimichi, Nagao, Ryuji, Seko, Noriko, Matsumoto, Kazuko, Tani, Yumiko, Terui, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894540/
https://www.ncbi.nlm.nih.gov/pubmed/33099791
http://dx.doi.org/10.1111/1346-8138.15655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894540/
https://www.ncbi.nlm.nih.gov/pubmed/33099791
http://dx.doi.org/10.1111/1346-8138.15655

Ejemplares similares